LifeSci Capital analyst Francois Brisebois assumed coverage of Avadel Pharmaceuticals (AVDL) with an Outperform rating and $21 price target The firm believes the company’s commercial investments are beginning to show benefits with improved persistency trends leading to a growing number of reimbursed patients on Lumryz. LifeSci sees further growth ahead and views Avadel’s idiopathic hypersomnia and low salt oxybate version efforts as upside to its price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals: Strong Sales Growth and Strategic Positioning Drive Buy Rating
- Avadel Pharmaceuticals initiated with an Equal Weight at Wells Fargo
- Avadel Pharmaceuticals price target raised to $20 from $13 at UBS
- Avadel Pharmaceuticals Reports Strong Earnings and Growth
- Avadel Pharmaceuticals price target raised to $18 from $16 at Deutsche Bank